Myriad Genetics, Inc. (MYGN) News

Myriad Genetics, Inc. (MYGN): $18.63

0.46 (+2.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter MYGN News Items

MYGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MYGN News Highlights

  • MYGN's 30 day story count now stands at 9.
  • Over the past 24 days, the trend for MYGN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about MYGN are BEAT, CHRS and GENE.

Latest MYGN News From Around the Web

Below are the latest news stories about Myriad Genetics Inc that investors may wish to consider to help them evaluate MYGN as an investment opportunity.

Myriad Genetics, Inc. (MYGN) CEO Paul Diaz on Q4 2021 Earnings Call Transcript

Myriad Genetics, Inc. (MYGN) Q4 2021 Earnings Conference Call February 24, 2022 16:30 ET Company Participants Nathan Smith - Senior Vice President of Investor Relations & Treasury Paul Diaz - President & Chief Executive Officer Nicole Lambert - Chief Operating Officer Bryan Riggsbee - Executive Vice President & Chief Financial...

SA Transcripts on Seeking Alpha | February 25, 2022

Myriad Genetics (MYGN) Reports Q4 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 0% and 0.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives

Highlights: Strong business performance despite COVID-19 headwindsRevenue of $160.8 million in the fourth quarter and $690.6 million for the year ended Dec. 31, 2021, up 4% and 24%, respectively Excluding revenue from divested businesses, revenue increased 19% for the fourth quarter and 34% for the year Diluted GAAP earnings per share (EPS) of $(0.10) and adjusted EPS of $(0.02) in the fourth quarter of 2021Ended the quarter with $398.8 million in cash, cash equivalents and investments SALT LAKE

Yahoo | February 24, 2022

New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test

Analysis shows combinatorial approach is more effective than single-gene testing at predicting sertraline metabolism in patients with major depressive disorderSALT LAKE CITY, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced today the peer-reviewed journal Psychiatry Research has published a new analysis of GeneSight® Psychotropic, the company’s mental health medication test, in its Feb. 2022 edition. The study sh

Yahoo | February 23, 2022

Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 1.64% and 11.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 17, 2022

Myriad Genetics to Release Fourth-Quarter 2021 Financial Results on February 24, 2022

SALT LAKE CITY, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its 2021 fourth-quarter earnings conference call on Thursday, February 24, 2022 at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day prior to the market opening. During the call, Paul J. Diaz, president and CEO, and R. Bryan Riggsbee, chief financial officer, will provide a financial overview and business update of Myria

Yahoo | February 16, 2022

Myriad Genetics (MYGN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 15, 2022

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

SALT LAKE CITY, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be presenting at two upcoming healthcare conferences. On Feb. 17, 2022, R. Bryan Riggsbee, chief financial officer, will participate in a fireside chat at the virtual BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference at 12 p.m. ET. On Feb. 18, 2022, Paul J. Diaz, president and CEO, and Riggsbee will participate in a fireside cha

Yahoo | February 14, 2022

Myriad Genetics' (NASDAQ:MYGN) investors will be pleased with their favorable 70% return over the last five years

It hasn't been the best quarter for Myriad Genetics, Inc. ( NASDAQ:MYGN ) shareholders, since the share price has...

Yahoo | February 1, 2022

Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference

SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will provide an update on the execution of the company’s strategic transformation and growth plans at the 40th Annual J.P. Morgan Health Care Conference at 2:15 p.m. ET on Jan. 11, 2022. Diaz will discuss the growing role of genetic insights in context with industry trends, new commercial capabilities and products that advance he

Yahoo | January 5, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5935 seconds.